Key result
Elevated RV glucose utilization on FDG-PET characterizes IPAH, and its decrease correlates with improved RVEF.
Why the study?
Does right ventricular glucose metabolism measured by FDG-PET correlate with RV function and help monitor treatment response in patients with idiopathic pulmonary arterial hypertension?
Cohort (n=48)
Does right ventricular glucose metabolism measured by FDG-PET correlate with RV function and help monitor treatment response in patients with idiopathic pulmonary arterial hypertension?
Increased right ventricular glucose metabolism measured by FDG-PET correlates with RV dysfunction and pressure overload in IPAH, and its changes may help monitor RV function after treatment.
RV FDG-PET glucose uptake changes may track RV response in IPAH; leaves open clinical utility pending prospective validation.
AIMS: Right ventricular (RV) glucose metabolism disorder in pulmonary arterial hypertension (PAH) has been studied using (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) imaging with inconsistent results. We aimed to quantitatively assess RV glucose metabolism and further identify its role of monitoring RV function in idiopathic PAH (IPAH) patients in a longitudinal study. METHODS AND RESULTS: Twenty-seven treatment-naïve IPAH patients and 21 healthy control subjects performed FDG-PET dynamic scan for quantification of the rate of myocardium glucose utilization (rMGU) and echocardiography for assessment of cardiac function. Right heart catheterization was conducted for IPAH patients for haemodynamic measurement. A subgroup of 14 patients repeated FDG-PET and echocardiography after 6-month treatment. RV rMGU was significantly increased compared with controls; while the rMGU in left ventricle showed no difference. RV rMGU was significantly correlated with pulmonary artery pressure, pulmonary vascular resistance, RV Tei index, and right atrial area, and negatively correlated with RV ejection fraction (RVEF) and tricuspid annular plane systolic excursion. Six of 14 patients with increased RV rMGU after 6-month treatment showed no change in RVEF, 6-min walk distance (6MWD), and RV Tei index; however, the other 8 patients with decreased RV rMGU demonstrated significantly increased RVEF and 6MWD and decreased RV Tei index. Notably, the change in RV rMGU of 14 patients was significantly correlated with the change in 6MWD and RV Tei index. CONCLUSION: Increased RV rMGU of IPAH correlates with RV dysfunction and RV pressure overload. The change in RV glucose metabolism may help monitor RV function after treatment.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2015) conducted a cohort in Idiopathic pulmonary arterial hypertension (n=48). FDG-PET imaging vs. Healthy controls was evaluated on Rate of myocardium glucose utilization (rMGU) and cardiac function. Right ventricular glucose utilization assessed by FDG-PET was significantly increased in 27 IPAH patients compared to 21 controls, and its decrease after 6 months correlated with improved RVEF.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: